ArticleJournal of neuro-oncology2026
Invasion/metastasis-related differentially methylated genes predict prognosis in diffuse gliomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify invasion/metastasis-related differentially methylated genes (DMGs) with prognostic relevance in diffuse gliomas and to develop a DNA methylation-based risk model for prognostic stratification.
methodsInvasion/metastasis-related DMGs were identified by integrating gene expression and DNA methylation profiles from public glioma datasets. Prognostic DMGs were screened using univariate Cox regression and log-rank tests, and a risk model was constructed and evaluated by survival analysis and time-dependent receiver operating characteristic curves. Independent validation was performed in external cohorts. Functional enrichment, immune infiltration, mutation, and clinical correlation analyses were conducted. Key genes were functionally validated in T98G and U251 glioma cells.
resultsTwelve prognostic DMGs were identified, and two marker genes, ERRFI1 and MYO1G, were selected to construct the risk model. The model showed prognostic value in the training cohort and retained predictive performance across independent validation cohorts. Enrichment analyses linked the risk signature to adaptive immune and inflammatory responses. High-risk patients had worse overall survival (OS), altered immune infiltration, and increased immune checkpoint expression. Knockdown of ERRFI1 or MYO1G inhibited proliferation, invasion, and migration in T98G and U251 cells. Preliminary Western blot analysis suggested that ERRFI1 knockdown altered EGFR/MAPK/ERK pathway phosphorylation.
conclusionThis study identifies an invasion/metastasis-related DNA methylation signature based on ERRFI1 and MYO1G that may provide complementary prognostic information and biological insight for diffuse gliomas.
Indexed as
Identifiers
42247199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.